Times Opinion: An erratic FDA is a threat to innovation

The article discusses how the Food and Drug Administration’s (FDA) erratic behavior, particularly concerning Moderna’s vaccine applications, is stifling innovation in the pharmaceutical industry. It highlights the FDA’s inconsistent stance on Moderna’s flu vaccine application and the broader negative impact on venture capital investment in new treatments. The editorial argues that unpredictable regulation threatens the ecosystem that fostered successes like Moderna, potentially leading companies to avoid risky but life-saving innovations.